CURE staff

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda.

FDA approved Lifyorli plus Abraxane, improving survival in platinum-resistant ovarian, fallopian tube and peritoneal cancers.

Five-year ICESECRET data show high recurrence-free rates with cryoablation for small kidney tumors, supporting a minimally invasive treatment option.

New findings from the phase 3 SENTRY trial offer encouraging news for patients with myelofibrosis.

Topical HT-001 reduced rash and irritation from EGFR therapies with low levels in the bloodstream and no serious side effects in patients with cancer.

Zegfrovy helped patients live longer without cancer growth and improved tumor response compared with chemotherapy in first-line lung cancer treatment.

An overview of stage 1 lymphocyte-rich Hodgkin lymphoma covers diagnosis, treatment options and side effects to help guide patient care decisions.

Dr. Hope Rugo and advocate Jonise Louis discuss new ADCs, biomarker testing, and patient-centered dosing for metastatic triple-negative breast cancer.

High-risk essential thrombocythemia is manageable with treatment focused on preventing blood clots and maintaining safe platelet levels.

FDA approves Opdivo with AVD for stage 3 or 4 Hodgkin lymphoma after trial shows improved progression-free survival versus comparator in untreated patients.

Talzenna plus Xtandi improved progression-free survival in metastatic prostate cancer, delaying disease worsening in a phase 3 trial.

A phase 3 study shows pimicotinib shrinks tumors and improves pain, stiffness and mobility in adults with unresectable tenosynovial giant cell tumors.

NCCN guidelines now include plus BCG for certain BCG-unresponsive bladder cancer patients, expanding treatment options.

The FOURLIGHT-1 study found that atirmociclib plus Faslodex significantly improved progression-free survival in patients with HR+/HER2- metastatic breast cancer.

A UCLA study found CAR-NKT cells eliminated endometrial tumors in models and showed stronger activity than existing immunotherapies, supporting further clinical development.

Survey shows 92% of eligible adults support coverage for colorectal cancer blood tests to improve screening access and adherence.

A phase 3 trial update for GLSI-100 shows a recurrence rate of less than 1% per year in patients with HER2-positive breast cancer after immunization.

Studies show Signatera ctDNA testing may predict recurrence and guide treatment decisions in anal and rectal cancers.

The CAPTAIN trial shows MRI-guided TULSA preserved erectile and urinary function versus surgery in localized prostate cancer.

Learn about male breast cancer, including common symptoms, diagnostic tests and how hormone therapy or surgery is used to treat this rare disease.

Stage 1 mixed cellularity Hodgkin lymphoma is often highly treatable with chemotherapy and radiation, with additional therapies available if the disease returns.

A study of 922 patients shows the Aida test predicts 10-year recurrence risk and helps guide radiation decisions for invasive breast cancer.

Preliminary INVINCIBLE-4 study data shows INT230-6 plus standard care may increase pathological complete response rates and improve patient safety.

Black Medicare patients with early-stage NSCLC continue to get surgery and radiation at lower rates than White patients, showing persistent treatment gaps.

Phase 2 interim data show NDV-01 produced high response rates and encouraging safety in patients with non–muscle-invasive bladder cancer.

The phase 3 persevERA study of giredestrant plus Ibrance missed its PFS goal, though positive data from other trials supports the drug.

FDA declined approval of retifanlimab for metastatic non–small cell lung cancer due to manufacturing issues at a third-party facility, not safety concerns.

The SUCCESSOR-2 study shows MeziKd improves progression-free survival for relapsed multiple myeloma patients previously treated with anti-CD38 drugs.

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

The FDA has received a new application for Anktiva plus BCG to treat BCG-unresponsive non–muscle invasive bladder cancer with papillary tumors.